de novo resubmitted that study in 1985. mr. campbell it went through the same peer process, so i'd ask exempt tend to be made part of the record without objection, that will be the order. it then had to be withdrawn again. according to this letter written to the journal editor. the reason was that philip morris had quote, issued an injunction against publication of this paper, unquote. the letter was from the editor. as you can see, mr. campbell. did you or did you not deny were you deny philip morris kept the noble study from being published. i will not deny that you did keep it from being published. yes, we did not in any way employ legal technique such as injunctions, but we did not. we did not choose to publish that. isn't it true, mr. campbell, that prior to the time that dr. noble submitted his study to the journal in 1983, his study had been reviewed by philip morris for publication. i believe that to be the case. yes. all right. in its press release, mr. campbell, philip morris states that it did not obtain an objection

francine: this is the man in charge of europe's most valuable company, novo nordisk, and its blockbuster diabetes and obesity drugs ozempic and wegovy. both contain the key ingredient semaglutide, revolutionizing the weight loss market and generating billions in sales. celebrities have helped their popularity soar. sharon osbourne, chelsea handler, and elon musk have all publicly talked about taking ozempic or wegovy, and they've had further backing from oprah winfrey. it's a global phenomenon, reaching millions on social media apps, including tiktok. but it's not without controversy, including possible side effects, high prices, and the company's lobbying efforts receiving criticism around the world. and in some cases, patients might also need to take the drugs indefinitely to avoid regaining the weight. chief executive lars fruergaard jØrgensen says obesity is a disease and thinks the company will learn from its growing number of patients. lars: when i ask the scientists, they say the priority and mechanism will tell you that it's chronic treatment. my personal view is that we will als

you have in front of you the de novo study. dr. de novo was studying the nicotine of rats in 83. he found that rats will self-administer nicotine when hooked up to an intravenous nicotine solution. in other words, they will work to get nicotine. and as dr. kessler told us in the hearing that he testified in self administration of this type is hallmark to addiction. i'd ask unanimous consent to enter in the record exhibit six. without objection, i will be released. mr. campbell before you as a police your press release that said the dr. de novo study showed exactly the opposite. i have a copy here which is a marked and it says that the noble study showed that nicotine is quote, in a class of non-audit active chemical compounds such as saccharin or water. i don't think any of us are ever going to find mr. campbell a study that shows rats or any other animals will self-administer saccharin or water intravenously as a way they do. nicotine. i ask unanimous consent to enter in the record exhibit seven. without objection, that will be the order. mr. campbell this is a letter from the d

they seem to have found a home around 885, 89, looks like novo has room to the down side.he money in the manufacturing capacity that lilly or novo has, the competition is increasing out there and just pfizer on the conference call was talking about -- talking up its obesity pipeline which is in granted earlier stages than either of these. >> for a while, though, the competition isn't a threat yet. >> for a while. >> nobody is close yet. but, i mean, the numbers continue to grow and grow, it's extraordinary that it hasn't plateaued at all but sort of keeps accelerating. so, i mean, they also have their own competition within their own, right -- they're trying to come up with their own oral. >> right. >> you have to think they are a pretty good candidate to win that fight maybe. i don't know. i'm long lilly, it is not cheap by any stretch, but staying in it. >> novo looks interesting, down 25% from recent highs, expected 25% earnings growth in the next couple years, trades at 25 times, you can do that math, guy, probably, right? to me this looks like a good one to take a sho

so, that one is tricky a lot of analysts out there are lowering estimates for lilly and novo, and the weak, especially versus other large cap pharma stocks i think a lot is baked in here we'll see what happens the volatility in these two stocks, you know, is something we really haven't seen before in pharma, at least on a day-to-day basis. but i would think if there's a little bit more weakness into mid to late october, there's going to be a good buying opportunity at some point. and for novo, especially, the valuation is t getting very compelling i think the stock is trading right around 25 times on next year's numbers and we know the growth profile accompany is extraordinary 25 times doesn't seem like a lot. >> and lilly's new cfo is out there in the market in a recent analyst meeting saying they think long-term margin in the high 40s is sustainable, jared so, related to that, but it was a fascinating week in terms of the compounders. and lilly has been very outspoken about action against it just thoughts on this and what this has meant obviously for those compounders, what it means

and it's a window which novo nordisk and eli lilly argue. look, we develop these drugs, we should make some money in that period. we should benefit. i agree with them, but i would argue they don't need to make quite as much as they currently do. we could regulate them. you know, at the moment, novo nordisk is now the most profitable company in, the whole of europe. so i think we should be, you know, prioritizing, getting the drugs to people who need them, not least because by many measures, obesity is the killer in this country. professor mander at harvard, who the food label that's on all food the united states sold in the us. so explain to me, presented with his calculations that obesity and food related illnesses. kill 678,000 american boys every year that's more all the american soldiers who died in all the wars of the 20th century and indeed the war in this century and. i mean, that is a staggering toll. that's, you know, not far off having covid every year. the covid pandemic, every year. right. and that stock, we shouldn't accept this

the main targets, novo nordisk's diabetes drug ozempic, as well as its obesity drug, wegovy.aro and zepbound. all in a class of wildly popular weight loss drugs known as glp-1s. the ozempic we brought from laver beauty cost $219, while real ozempic goes for nearly $1,000 for a month's supply. the company's website in corporate documents claim the operation is located in boulder, colorado. but the ozempic we ordered from laver beauty was shipped via dhl from this office building in china, off an elevator and behind this unmarked door, right to us at cnbc headquarters in new jersey. let's open it up and see what we have. plain cardboard box. it doesn't appear to have any refrigeration. though it's supposed to be refrigerated. this might have been a refrigeration pact. it dud say ozempic on it, 1 milli milligram. and here's the pen. looks like the real thing. let's see what's inside. was this real ozempic diverted to the u.s. or a fake? and why did it come from china, when the company has a colorado address? we'll answer that question, but first, our investigation brought us to

i think ultimately, that's what you see here novo already broke novo broke pretty hard it's down 22, the highs. it is probably oversold. we have to get more skeptical of that one as it rallies really an opportunity to be reducing exposure. >> 123 in novo is a level we talked about, obviously through that, down to 116 today. yeah, maybe you'll catch a bounce back to that prior resistance, however, you look at a chart, and there's a very good chance you have a bit of a head and shoulders formation here, melissa lee, so, keep that in mind >> all right there's a lot more "fast money" to come. here's what's coming up next. >>> roasting starbucks what billionaire investor bill ackman had to say about the coffee chain ha as the company looks to percolate things with a new ceo at the helm. >>> plus, a shock to tesla's stock. shares heading downhill after the ev maker's latest delivery numbers what the metrics mean for the business, and the next catalyst for the name. you're watching "fast money," live from the nasdaq market site in times square. cf1 o ah, these bills are crazy. she has no id

you can--we tried so hard with our dp and our director mar novo to show jalisco and guadalajara in thistiful light. so, i'll let marta talk more about the story and the sisters's relationship, but we're just so happy to be at the festival and have people come and see the film, and they're going to laugh, they're going to cry, and it's just a feel-good movie with a lot of family values and messages. damian: and we'll get to you in a second, marta, but, denisse, you could have shot this in the mission district in san francisco, or in olvera street in los angeles, but you're in the heart of it. you're in mexico. denisse: yeah, yeah, yeah, we did. we were in mexico in guadalajara for five weeks, shooting two weeks in the city and then three weeks in this little town. so it was just a really beautiful experience to have the cast and crew. we have marta, we have valeria maldonado, virginia novello, cristo fernández, and just had--and also some other amazing actors. so it was just like family. like, the movie, it's about the sisters doing the pilgrimage, and the real life of all the crew, it w

and the reason for that is, novo has had a couple of hiccups this half, which is very unusual. the cb-1 data was not very good, at least the headline numbers were not very good and then their peptide oral seems like it could face challenges so, this is really the first time, where maybe viking slides into first or second position in oral, with lilly >> is the number one challenge the manufacturing process? >> i think so. i think that's the biggest hurdle >> okay. >> so you i was thinking you were going a different way what's going to happen for the company? that wasn't what you were going for. in terms of are they -- >> a takeout or what not i know they raised money higher than here, but i mean -- obviously it's the most exciting space in i don't know how long, so -- >> right. >> how big a risk will somebody take, do you think >> well, it's an $8 billion company, they've got a billion in cash, so they'll tell all of us that they believe they have enough money to fund the injectable and the oral trials basically through approval at that point, they'll need a lot more for manufac

it does say ozempic on it, and here's the novo northis logo. was this real ozempic or fake? why did it come from china when the company has a colorado address? we'll answer that question. but first, our investigation brought us to the uk, where hundreds of counterfeit ozempic pins have been seized. it's hard to tell what's real and what's not. andy is deputy director of criminal enforcement of the health care products regulatory agency. >> which one is genuine and which one is the fake? >> reporter: this one is real. the other one with the purplish pen isn't. >> it is a very crude copy, and it's enough to make people who don't have this level of knowledge and don't have the capacity to inject this into themselves. >> reporter: 869 counterfit pens were seized. >> these are manufactured, and made to look very much like ozempic pens. >> reporter: now back to the ozempic we bought on line. novo nordisk says it appears to be legitimate product and was produced for the chinese market during late 2023 and '24, therefore it would be unauthorized for the u.s. market. the company went

lilly, by the way, reports at the end of the month, novo at the beginning of november. >> yeah, i thinka on the new prescriptions is something that i think is also just coming in, and, but it gets back to me, the competitive landscape, and so, again, if you're talking about lilly and novo, what is the growth factor out in '25 and '26? and i know that they have other, you know, arrows in the giver, but for those stocks, obviously, it's been disproportionate >> just to hims and hers for a second 16 and change percent short interest i don't know if that means t that -- okay, there was some covering on this news and that's why it held up better, because i agree that it would have been down more. >> good point there. >>> up next, final trades. growing old is part of the journey, even when you have heart failure. but when he had shortness of breath, carpal tunnel syndrome, and lower back pain, we wondered, could these be warning signs of something bigger? thank goodness we called his cardiologist because these were signs of attr-cm, a rare and serious disease... ...that gets worse over time.

sevastopol, among other things, she visited the novo-khersanez museum and temple complex and the art which opened this year, according to valentina matviyenko, this educational institution is unique and has no analogues either in russia or in the world. the art school in sevastopol has produced an incredible piece of work, there are no analogues to it, not only in russia, but in the world . and here is what he did. the next day after its proclamation. sergey lavrov noted the dynamic, developing nature of the relationship between the two countries and said that xizen ping is expected at the brics summit in kazan in october. moscow was the first to officially recognize new china, and in our country beijing has found a reliable friend who has helped it at the initial stage of state building. i am pleased to note that in the current geopolitical realities. the russian-chinese comprehensive partnership and strategic interaction demonstrates absolute stability and maturity, continuing to promote the comprehensive development of our countries, increasing the well-being of our citizens. coop

. >> what does it mean for lillian novo. >> i was interested in the clip eli lilly only down 2% clearlye 800-pound gorilla in the space not too concerned about the competition but the field is widening. >> enough for everyone to make money. >> i'm looking for a stock pick you say you like schneider and i love pretzels but were not talking about the pretzels. >> of honeywell and even trades about 26 times 115% i been doing very well good momentum and like j.p. morgan puts it the simplest cleanest best way to play a.i. electrification in all the trends. snyder electric. electric cars and electric lawnmowers. >> data centers. schneider electric, make somebody rich with the great stock picked. >> nobody was richer than j.p. morgan and i'm looking at j.p. chase the stock had fantastic earnings ten days ago and hasn't done much since the initial blue the whole sector looks like it's going to break out, j.p. morgan looks like it's going to lead at the good to great time to look at banks in general j.p. morgan specifically. great ideas and thank to read more checkout appearance.com. that's all

it says ozempic on it. 1 milligram, here's the novo nordisk logo and the pen.porter: was real ozempic? a colorado address. we answer that question. first, our investigation brought us to the uk where hundredses of counterfeit ozempic pens have been seized. hard to tell what's real and what's not. the fakes are that good. deputy director of criminal enforcement for the medicine and enforcement agency. >> which one is genuine and which is the fake. >> reporter: this one is real. the other one with the purplish pen isn't. >> it is to us a very crude copy, not in any sense at all but enough to make people who don't have the knowledge and comparison to make inject this into themselves and cause themselves harm. >> reporter: a total 869 counterfeit were seized relabeling insulin pens. >> completely counterfeit products manufactured somewhere. we don't know exactly where, and made to look very much like ozempic pens. >> reporter: now, back to the ozempic with bought online. novo nordisk says the ozempic we received appears to be a diverted legitimate product produced

the moments of real intimacy, real feelings in the kitchen, wells of m, o g's martina, half those novo talks about a complicated emotional situation and about the friendship is pawn shop and about love, how the book about lo, mein was in, and global imbalances due by the english profession. and with this maci now have to, has created a change of pace that spans the wo. the 5 more novels made it onto the short list for the german book prize. let's find out more about them and meet their authors. there hasn't been, it has to be the head is because it combines so many different temperaments. i'm the one can tumble wildly through time and space with it sounds to have some kind of see where this book is. it's already of the kills and deliberately so with a know it's oh toy her as a companion, the 1st person to write to inbox on a road trip through space out and find to see with the big i drove into the field modeling at my own speed and the grooves left behind my breaking was not accidental, but wonderful, precise and deep. and with that, i fell into a field of flowers and slend tights as m

. >> novo nordisk la empresa fabricante de aseptic, estÁ realizando dos ensayos clÍnicos para evaluar Último grito de la moda para los perros que se agotÓ el mismo dÍa de su lanzamiento. entÉrese por quÉ y hablamos con un joven y premiado fotÓgrafo hispano que a travÉs de su lente explora los fondos marinos y capta la vida de sus infinitas especies. en el video del dÍa nos llega de la guardia costera de estados unidos. vea usted, se trata de la laboriosa evacuaciÓn en helicÓptero de un hombre enfermo de un buque pesquero que planeaba en aguas de hawÁi a 78 millas de la costa kahului, en la isla de maui. >> el hombre de 35 aÑos empezÓ a sentir un fuerte dolor abdominal, por lo que se dio a la alarma para que vinieran a rescatarlo. fue llevado a un hospital y estÁ en condiciÓn hospital y estÁ en condiciÓn estable. (♪♪) ¡hola! cómo están? ¿estás listo? ¡adams elementary, vamos rams! creo que él también necesita uno. ¿qué piensas? ¡sí! esto no es solo protección contra la gripe. esto es un vecino que se preocupa por ti. programa las vacunas contra la gripe y el covid-19, para ti y tu fami

and so i repeat once again, what's up there are nuts, a small takmachka, in robotyn, novaandriivka, novothe list, and what else they have, in particular, that every day where... they get, and there they get rszv, for example, there this hail can just drive up, and it just pours, pours, there just, well, without stopping, that's their tactic, just parched land, it continues, that's why the general staff was several times, mr. dmytro, several times we the general staff had already heard reports that the enemy was concentrating there and preparing to offensive exactly in the direction of zaporozhye, what do the military actually say? and how big is it, how does it feel now? well, it is felt, of course, by our defenders, this strengthening in the zaporizhzhia direction, but the key thing is to note that the language is not in question, yes , what the spokesman already said there, it was announced that what concerns the zaporizhzhia direction in particular, that we are not talking about yet, yes , about their grouping there for there, you know, offensive breakthroughs, and it's about... const

today, semaglutide manufacturer novo nordisk said it did not condone, suggest or encourage misuse of regulator is calling for anyone experiencing unwanted side effects to report them. sophie hutchinson, bbc news. still to come new plans for an independent regulator for football in england we will look at how it could work and, why do because? there is a new theory and it's particularly romantic. around the world and across the uk. this is the world today on bbc news. another attempt to create an independent regulator for elite men's football in england is being made with ministers say they have strengthened previous plans. however the premier league says it remains concerned about what it calls the unprecedented powers to intervene in the game. the culture secretary says the regulator will only do what's necessary for the financial stability of the game. earlier i spoke to football finance expert tom bason. he's assistant professor of sport management at coventry university. it's much of the same, really. there are a few things in there that perhaps we weren't necessarily expecting.

ukrainian armed forces prevented our troops from advancing from the north in the area of ​​marinka and novo-mikhailovkast. last summer, the militants counterattacked in the area of ​​the vremevsky salient. now in ukraine the situation in ugledar is called a local collapse of the front. in addition to the ukrainian armed forces soldiers from the seventy-second brigade, who left ugledar without orders, our fighters destroyed mercenaries from poland and the baltics in the city. retreating, the enemy strikes. about the liberation of the city of ugledar, and such commands have already been given on my part. well, this is the first concert in the liberated ugledar. alexey ivanov, roman khrolenko, igor fedorenko, andrey kolobayev, natalya mushtakova, sergey prokofyev, the first channel donbass. in addition to ugledar, the russian army liberated five more settlements in a week - this is verkhnekamenskaya dpr, there is also nelepovka krutoy yar, and also makeyevka in luhansk people's republic and the village of vyshneve in the kharkiv region. the enemy is suffering huge losses along the entire front line, with

today, semaglutide manufacturer novo nordisk said it did not condone, suggest or encourage misuse ofanyone experiencing unwanted side effects to report them. sophie hutchinson, bbc news. our top story this evening: with less then a week to go before the budget, the chancellor rachel reeves says she will change the debt rules — which are self imposed — in order to free up billions of pounds for infrastructure spending. the weird and wonderful world of tim burton goes on display at the design museum in london coming up on bbc news, erik ten hag's manchester united have travelled to istanbul to come face—to—face with their old managerjose mourinho. the fenerbahce manager has said united should expect a tough match in the europa league later. the government's introducing plans to bring in what it is says will be a strengthened independent regulator for men's football in england. they say the new plans will put fans "back at the heart of the game" by giving them a bigger voice in their club over decisions like changes to ticket prices and plans to relocate home grounds. here's our sports

lily's -- eli lilly's leaders and get in and buy the dip and winner in the race between eli and nov novos. stuart: after a painless injection, pills win. next one is inodata. >> this is a pick and shovel way to play and ai with contracts with five of the seven in the mag seven and growing earnings at 60% plus right now and great way under the radar and small cap company playing into the trends of getting more attention and it's going for ai in a while. ai sectioners going through this countless times. stuart: is the money there to build ai? >> not a single solution that provides that and diversified power grid and supply. reporter: the chinese student used university of michigan id card at the school so register to vote and we don't know if that'll count and it all unfolded and on the university of michigan's campus in ann arbor cpi happened on sunday with the -- ann arbor on sunday and campus polling low assigned to out in ann arbor and haven't released his name and he's facing very serious criminal charges. back out here in michigan, we can tell you things are coming down to the wire a

. >> i don't love novo nordisk and prefer eli lilly and these are ppeptides and heart disease, sleepea and indications of canser and doesn't surprise me we're finding it could cure -- or help slow the progression of alzheimer. stuart: can do all this. that's great. >> looking at biology, it makes sense and you're addressing obesity and downstream negative health affects from diabetes and obesity that's resolving. stuart: thanks, lou. juul, j-u-u-l, that's a vape and receiving payments from a 300,000 class action lawsuit and some are sharing the news on social media. what are tay say -- they saying on the video? >> some claim they didn't know there was a class action lawsuit and surprised when the money hit their venmo accounts and look at examples of the tiktoks folks are making. >> i received $1100 in the juul class action lawsuit. >> your money is probably in your bank act right now. >> $6,000 is a ton of money. >> probably going to use it to buy nor juuls. >> there's an entire genera of tiktokers from simple celebrations and explainers how this all went down and one of these came

both eli lilly and novo notice rely on norfork, the company shut down by the strike. that it is now going to use airfreight with shortages while eli lilly has not said but the contingency plans are. analysts say in the short-term the weight loss drug should be widely available, if this drags on, it will change dramatically. stuart: lindsey davis compared tim walz's debate performance with another disastrous event. watch. >> reminded me of the june 27th debate when kamala harris said of president biden it was a slow start but a finish. there were uncomfortable moments. stuart: that's not good for the harris camp. brian kilmeade takes it on next. ♪ ♪ when a tough cough finds you on the go, a syrup would be... silly! woo! hey! try new robitussin soft chews. packed with the power of robitussin... in every bite. easy to take cough relief, anywhere. chew on relief, chew on a ♪ robitussin ♪ we really don't want people to think of feeding food like ours is spoiling their dogs. good, real food is simple. it looks like food, it smells like food, it's what dogs are supposed to b

pfizer receiving approval for vaccine 18 to 59 who are at increased risk for the virus novo fda request copies of its weight loss drug ozempic. >>> continued enthusiasm around stocks making strategists nervous and pointing to index futures hitting its highest level since mid july of last year the same setup ahead of a three-month sell-off that saw the s&p 500 fall by 10%. they suggesting that less capital is at risk for much more let's bring in victoria green, foundsing partner and chief investment officer and a cnbc contributor also good to see you. >> good morning. >> what do you think about that citi note getting nurves about some of the positioning? >> sure. we will all a little bit nervous. the farthest we have gone down is 8% and hitting the best quarter in the history of the s&p 500. november is the strongest seasonal month in december earnings so far have been pretty decent i think it's not quite the same and be a 2018 situation. i don't see 10% in the cards with so much 6.5 trillion in money markets. i think it's a little bit overblown and there is likely we will have a lot of

we talked about alcon, but novo nordisk is a leader in the gl-1 space which is a transformative platformthe treatment of diabetes and other areas. so we're not paying so much attention to the macro, as we are looking at the fundamentals of the businesses that are this those countries. and in europe, a lot of businesses have a lot of exposure outside of europe, simply because growth in europe has been slower over the last two decades. >> yes, it has. emily, i love it. a brand new name, alcon. we're watching it. have a great day. thank you. >> you too, brian. >>> coming up, ai can either be a killer or a catalyst. a lot of it depends on the industry you're talking about and the business model. and another bonus mystery chart. that name you're looking at could be in trouble. plus, we head to break. one group today that is working has to do with the blooming onion. restaurants and blooming brands, cheesecake factory, brinker, they're all up very nicely. a little r ireauntunn stras today. we're back. the same gear,earing you feel a sense of connectedness and belonging right away. and our shir

in july, they both wrote an op ed criticizing eli lilly and novo nordisk for the high cost of their weights drugs. >> the new ceo of starbucks is calling for a business strategy overhaul, as the company continues to battle a slump in sales. the world's largest coffee chain disclosed today in missed earnings expectations for the fourth quarter, seeing steep setbacks in some of its biggest markets, the wall street journal reports. that includes a 10% drop in u.s. transactions and 14% drop in china. they also suspended financial guidance for the next fiscal year. starbucks already lowered its sales expectations twice this year, prompting ceo brian niccol to say they need to fundamentally change their strategy. >> for so many fall favorite season of the year. and perhaps this is why. get a load of this sunset over san francisco this evening. what a gorgeous view. heather gregg, are you seeing this? it's gorgeous sunset about a half hour ago and wow, that is a nice sight for sore eyes. let's talk about storm tracker two here. we do have an active scene, but it's not here in the bay area. we are

. >>> shares of hims and hers shares down after novo seeks ban on compounded glp-1s you are tagging lillyce the middle of july-ish it's not like it's cascading lower, but it's moved from 990 down to 904. one has to wonder, i mean, the alzheimer's stuff, without question, you should flag. obviously, a glp-1 story, but they report earnings on the 30th of october -- tim. >> boo >> boo >> thank you very much by any metric, very expensive stock. they better say some great things to hold only this 900 level. i think it can trade lower from here >> didn't you say october 30th >> he did. >> and that's why i was slow to my boo >> i didn't understand, why are we saying boo? >> close enough. >> the eve of boo. >> i agree with the boo on lilly, though. and it's a case where the valuation maybe starting to catch up to it we still really haven't heard that the competitive landscape makes it more than a two-horse race, but it will be. >>> we have some more coming in >>> we have some more coming in on tesla right now, which clem's not a morning person. or a... people person. but he is an "i can solve thi

and potentially on the glp-1s, but it's been only a year really since both lilly and novo's drugs have been approved i think it's a little early for that but it certainly could be a factor >> it's just a situation where many users are frustrated by the experience of their health coverage and yet stocks are struggling it seems like there should be a winner and then you get to what's happening on the medicare front and medicare advantage and humana stock is down 41% this year bertha coombs has been doing some great reporting on this what's going on on that front as this is the time of re-enrollment? are they being overused as well? are they going away? what's happening >> yeah, i think they're being overused so much has to do with medicare advantage rates and how that translates into numbers. and in terms of financial modeling and with when we look at the procedure volume effect, you know, that we talked about earlier, the medicare markets have not been this challenged in quite a long time. you've seen humana reassess or recalibrate its earnings several times already this year and so i t

we have to ask yourself is a vote for trump or novo at all the way we honor their lives? if that is the case, it does not sound like freedom to me. in any other profession or arena, trumps criminal track record and a moral character would be embarrassing, shameful, and disqualifying. so i hope that he will forgive me if i'm worried we will blow this opportunity to finally turn the page on this ugliness once and for all. because if donald trump is president again, at some point or another, that ugliness will touch all of our lives and it will not matter what you look like, how you worship, who you love, and how you vote. if you don't make 6, 8, or 12 figures, if you are not famous, if you criticize or disagree with him in any way, if you are not his equal or relative to his ambitions, i promise you he will not think about you when he gets into the oval office. that will have real consequences for all of us. if your town gets hit in national disaster, who do you want looking out for you? is it donald trump, who is spreading so many lies and conspiracies about climate change

. >> well, i mean, maybe as an individual name like novo nordisk, that's an international name. we're looking at the index level, the reason why international equities -- at like these companies are cheaper than the s&p. the cheaper than the s&p for the last 14 years because there is no silicon valley in europe. there's definitely not a silicon valley in china. i mean, if there is, they squash is down. you know, like in a country like france who can't fire anybody, you have structural issues where these companies are not able to grow and innovate as quickly as the u.s. and i think -- you think the u.s. has a lot of regulation, there is so much regulation in europe. and i think that is the reason why the multiples are lower. and i think if you buy the s&p, know that, what is it, i mean, liz and -- 55% to 65% of revenues of the s&p comes overseas. i think also if you own large caps in the u.s. you get china exposure, you get international exposure. i don't want to deal with the currency, which always can whip everybody around. so i like to do probability investing. that's going to

show me first of all show me novo nordisk down just about 1.2%.hat's going on with that company, that stock, ashley? ashley: we know it well don't we? it's the weight loss drugmaker. it is asking the fda to prevent other companies from developing cheaper copycat versions of their wegovy and ozempic injections. they argue that the medications developed are very complex and too complex, in fact, to be made safely. the stock itself down just over about 1.25%. meantime take a look at m-phase, the green energy people. they reported this morning, offered weak guidance also a 30% drop in revenue over the last 12 months. that in turn has led to a series of downgrades from analysts. rbc slashing its price target for instance from 100 bucks to 85. it's atria 80 right now, and down as you can see , 12%. there are also concerns about a drop-off in demand for the company's products in europe. none of that helping the stock today and take a look at aviation, they are the air taxi people. the faa has set rules for them to operate in the united states. it's good

in july, they both wrote an op ed criticizing eli lilly and novo nordisk for the high cost of their weights drugs. >> well, barry, whether kind of feeling like fall out there, a bit of a chilly start in the morning hours, but overall a nice afternoon with temperatures kind of on the mild side, 60s and some 70s. we had some stubborn fog though, near parts of the coastline closer to san francisco earlier this afternoon, and still some leftover patches out there. highs this afternoon, only in the 60s. 70s the warmest locations in the upper 70s. tomorrow should be just a little bit warmer. now this is the time of year we look for a change in the weather pattern that could bring rain chances. as we take a look here. we'll put this into motion into wednesday, thursday and friday. bunch of zeros covering the bay area into the weekend, especially by sunday. there is a slight chance of a sprinkle or a light shower, but clearly the main action is not here. but it's up to our north, up along the north coast, closer to del norte county. so we'll be watching out for those changes, but definitely some m

when do you expect that to be something that's relevant for actually making a dent in the road for novodata that we're going to get before year-end, to me, that's the biggest one. we've already seen a lot of good data from viking. they're kind of out there, they're going into phase three. i think they like fairly credible. >> meritide. >> right. i believe that could be something that winds up being discussed as a real competitive threat, if the dosing and the safety are good, and amgen can really market this as a less frequent injection, and the numbers look fairly comparable, i think that will be for a large cap pharma, large cap bio tech player that's credible, with a big sales force, that could be it. >> all right, you're like honorary trader here. >> he is. >> would you rather -- >> nice. nice. >> don't screw this up, by the way. >> lilly or amgen here? >> oh, my gosh. i think i would rather take lilly, i just don't love the variability with amgen. we don't know what we're going to get. i don't love the risk profile, because i truly don't know how to handicap the move. how much it c

novo nordisk's, not lilly, but there's an uncertainty that the fda can basically just dictate their futurew a lot more about this stuff than i'll remember, or something like that, whatever that expression is, but -- to me, it -- that they're able to get out there and actually be making their own version of this and the fda -- think about the fda process for so many other drugs and this seems to be a little willy nilly. >> eli lilly has said that all dosages of its drug tirzepatide are available right now, so, it is not in shortage, so -- the company is weighing in. i don't know who you believe. the company says it's not in shortage. >> why do you need the compounders? >> why would you believe hims or hers? all right, be sure to check out "ozempic underworld." you can scan the qr code on the screen, or go to cnbc.com. dan -- >> i'm doing it right now. >> you watched it. "big shot?" i loved it. watched it three times. >> up next, final trades. it's time. yes, the time has come for a fresh approach to dog food. everyday, more dog people are deciding it's time to quit the kibble and feed their

in july, they both wrote an op ed criticizing eli lilly and novo nordisk for the high cost of their weight loss drugs. >> a deadly e coli outbreak has now been linked to mcdonald's. at least one person has reportedly died, with dozens reportedly falling ill across several states, although no cases have been reported here. in california. the cdc says the outbreak is linked to mcdonald's quarter pounders and slivered onions are the likely source of the contamination. mcdonald's says it is that it has now stopped using the onions, as well as quarter pound beef patties in several states, according to a statement. while this investigation is ongoing, an iconic restaurant chain is announcing closures. >> denny's telling investors that it will shut down 150 underperforming locations nationwide. about 50 locations will close by the end of this year and the rest by the end of 2025. it's also allowing franchise owners the option not to stay open 24 hours a day. you'll recall the denny's on hegenberger road in oakland shut down in february after 54 years in business. stocks were mostly unchanged toda

is already in short supply and that would be weight loss drugs, the strike is forcing ozempic maker novoip in ingredients via air freight. ahara offers doctor-prescribed glp-1 medication. let's find out what it's like for a smaller company. joining us now is cofounder and ceo julie wainwright. she founded therealreal. julie, i know you work with u.s. pharmacies who put the compounds together, but what are you hearing about the actual ingredients that come in from over overseas? >> you know, so far everything is good, and we're ready to roll. i'm excited about it because we are working with compounding pharmacies that are licensed by state which actually keeps the drug cost significantly lower than ozempic and wegovy. liz: you have worked in all kinds of companies in your and many of them import-export. we've got this supply chain situation now rearing its head once again. we're hoping, certainly, that both sides of this fight over the ports and the longshoremen can come together soon err -- sooner rather than later. what do you keep an eye on as a see wrote when it comes to things that a

novo passit double action against irritability and anxiety. buy in gorzdrav pharmacies. are these potato and these, i want this variety, i still have to myself. the luna of such snacks. you have not seen them yet, very tasty and hyped, unique forms, try at my expense, 100,000 people will receive 500 rubles each. deluna, hyped snacks, tastes and forms, choose deluna, the path to hype! every 15 minutes, wherever you are, whatever you do, whatever did not strive, every 15 minutes game, hunting, your chance to change everything, the main trophy from 340 million, hunting, check your instinct, one hundred! feel life and not a pain in the stomach, what power can the internet have, only in t2 it can become a currency, double benefit in your hands, now gigabytes and minutes, like money in your accounts, taxis, breakfasts, and gasoline, get it easily for gigabytes, this is just shine from liamax. you will defeat dirt on white sneakers simply and quickly. clean solidified fat from a plastic kettle and the metal surface of a toaster. you will return new type of stainless steel produ

separately o novo nordisk's diabetes drug cut heart risks in patients dr.at's happening with avian flu >> that works we can start with the weight loss drugs certainly. >> novo nordisk this new oral pill looks like it's cutting risk of heart disease and many other things does this come as a surprise >> r no. it's a good result remember with this pill you're dealing with a lower dose of the active ingredient than the injectable formulations. so even though this pill is 14 milligrams versus 2.4 you get in wegovy how much of the drug is actually getting into the drug is less. only about .4% of the drugs from the pill get into the blood. so to see this kind of risk reduction in severe cardiac events like heart attacks and strokes with less exposure to the drug, much less is getting into the blood and patients exposed to less of the active ingredient that's a good result. a 20% risk reduction with wegovy, that was at 2.4 milligrams, that was obese patients this study was done with patients with diabetes but not necessarily overweight. >> i know they want to get t

will address all of that as i sit at the bart at the novo hotel -- as i sit at the bar at the novo hotel we catch up with andrew sheets of morgan stanley, cameron dawson of new edge and amanda lynem of blackrock and highlights from lisa's conversation later this morning. equity futures just about positive by one third of 1% on the s&p 500 and the 10 year, we add some weight to that yield. up a basis point. thank you for choosing bloomberg tv. this was "bloomberg surveillance." ♪ it's our son, he is always up in our business. it's the verizon 5g home internet i got us. oh... he used to be a competitive gamer but with the higher lag, he can't keep up with his squad. so now we're his “squad”. what are kevin's plans for the fall? he's going to college. out of state, yeah. -yeah in the fall. change of plans, i've decided to stay local. oh excellent! oh that's great! why would i ever leave this? -aw! we will do anything to get him gaming again. you and kevin need to fix this internet situation. heard my name! i swear to god, kevin! -we told you to wait in the car. everyone in my old squad has

i think it's linked with novo nordisk. going to india, big cnbc india anniversary, there's a three-day conference and the stock's down. what is that about eenui. >> we're going to get cut off here this increasing battle between qualcomm and arm - >> can we say that i got a dossier on that. >> let's set it up and we'll get the opening bell and come back to it. basically, arm has given qualcomm a 60-day notice of cancellation of what is their architecture license agreement and if they were to stop getting the ability to actually use that license, a lot of what qualcomm produces would no longer be able to be sold, conceivably. >> full stop. >> they've already been in litigation they continue to be about a separate issue let's get the open out of the way and come back. >> this is probably the biggest battle we're going to face this is zero sum now >> let's get the opening bell on the cnbc realtime exchange the big board, the new york liberty celebrating their first wnba championship. big parade today, jim, coming down broadway

so i think this is the global phenomenon enterprises are jumping on board, you know, novo nordisk isvidia, it is a global phenomenon, but as i mentioned, that in order to be successful in this, you can't just be successful in semiconductors, right. you have to be successful in the underlying systems, integration technology and networking and optics and software and development and other important part of what you mentioned is you need scale you need to be able to work very well with the supply chain because this is not going to take just one player, it is going to take many different players coming together and putting out this technology with a lot of liability that's the only way to scale it across the broad base of cloud and enterprise and software entities. >> blackwell's fixed, that didn't take long, right? and you expect the yield to get -- what does that mean, the yield will get better for blackwell? >> initially when they put the blackwell product out, there was an issue in just the underlying semiconductor, so they have fixed that and we are now expecting blackwell to go fro